new glp 1 drug Diabetes Patients Also Struggle to Access GLP-1 Agonists New study shows popular GLP-1

There is also concern about medication adherence in a population that may struggle with consistent self-care behaviours

Overall, while pharmacovigilance reports have described a range of psychiatric symptoms, real-world evidence to date does not support an increased risk of suicidality with GLP-1 RAs in patients with type 2 diabetes

A representative for Novo Nordisk told Scientific American that the company hopes to see FDA review in 2026

Less bulk, fewer contractions, fewer trips to the bathroom

Before, during, and after switching treatments, patient communication and reinforcement of educational messages are vital to ensure a smooth transition

[DOI] [PubMed] [Google Scholar] 714.Burmeister M.A., Ayala J., Drucker D.J., Ayala J.E